Background Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at …

Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is
the most common oncogenic driver in advanced non–small cell lung cancer, occurring in …

KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …

Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were
among the first cancer-initiating genes to be discovered. Of the three RAS family members …

The KRAS gene (Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that
encodes a small GTPase transductor protein called KRAS. KRAS is involved in the …

KRAS mutations are the most common genetic abnormalities in cancer, but the distribution
of specific mutations across cancers and the differential responses of patients with specific …

The three mammalian RAS genes (HRAS, NRAS and KRAS) encode four proteins that play
central roles in cancer biology. Among them, KRAS is mutated more frequently in human …

KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles
varies between cancers from different sites, but it is unclear whether allelic selection results …

Purpose: Activating missense mutations of KRAS are the most frequent oncogenic driver
events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly …

Lung cancer is the leading cause of cancer deaths worldwide, with non–small cell lung
cancer (NSCLC) accounting for 80% of all lung cancers. Kirsten rat sarcoma viral oncogene …